Delcath Systems (NASDAQ:DCTH) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Delcath Systems (NASDAQ:DCTH – Get Rating) in a report released on Sunday. The firm set a “sell” rating on the stock.

Separately, Canaccord Genuity Group cut their target price on shares of Delcath Systems from $24.00 to $20.00 and set a “buy” rating on the stock in a research note on Monday, April 11th.

Shares of NASDAQ DCTH opened at $4.56 on Friday. The firm has a market cap of $36.06 million, a PE ratio of -1.27 and a beta of 0.53. Delcath Systems has a 12-month low of $4.30 and a 12-month high of $13.50. The company’s fifty day simple moving average is $5.84 and its 200 day simple moving average is $6.99. The company has a quick ratio of 2.70, a current ratio of 2.93 and a debt-to-equity ratio of 2.55.

Delcath Systems (NASDAQ:DCTH – Get Rating) last issued its earnings results on Tuesday, May 10th. The company reported ($1.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.88) by ($0.12). Delcath Systems had a negative return on equity of 246.07% and a negative net margin of 764.84%. During the same quarter in the prior year, the business earned ($1.04) EPS. On average, equities analysts predict that Delcath Systems will post -3.15 earnings per share for the current year.

In other Delcath Systems news, COO John Purpura acquired 5,000 shares of the company’s stock in a transaction on Monday, April 11th. The shares were purchased at an average cost of $6.59 per share, with a total value of $32,950.00. Following the completion of the purchase, the chief operating officer now owns 23,721 shares of the company’s stock, valued at $156,321.39. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Steven A. J. Salamon purchased 6,000 shares of the company’s stock in a transaction that occurred on Thursday, May 12th. The shares were purchased at an average cost of $4.90 per share, for a total transaction of $29,400.00. Following the completion of the transaction, the director now directly owns 29,424 shares of the company’s stock, valued at $144,177.60. The disclosure for this purchase can be found here. Insiders acquired 23,400 shares of company stock worth $136,133 over the last ninety days. Insiders own 16.76% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Dimensional Fund Advisors LP bought a new position in shares of Delcath Systems during the first quarter valued at about $75,000. Virtu Financial LLC bought a new position in shares of Delcath Systems during the fourth quarter valued at about $114,000. State Street Corp lifted its position in shares of Delcath Systems by 70.3% during the fourth quarter. State Street Corp now owns 25,200 shares of the company’s stock valued at $195,000 after purchasing an additional 10,400 shares in the last quarter. Susquehanna International Group LLP bought a new position in shares of Delcath Systems during the fourth quarter valued at about $209,000. Finally, Millennium Management LLC bought a new position in shares of Delcath Systems during the second quarter valued at about $405,000. 21.93% of the stock is currently owned by institutional investors.

About Delcath Systems (Get Rating)

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.

See Also